Regeneron Pharmaceuticals (REGN)

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 10.5% in the afternoon session after its experimental cancer treatment failed to meet t...

Regeneron has been treading water for the past six months, recording a small return of 3.4% while holding steady at $717.22. The stock also fell short of the...

The competition is far behind.

This milestone came with an asterisk.

Regeneron's first quarter performance delivered revenue and non-GAAP earnings per share above Wall Street expectations, as management cited strong commercial...

Regeneron is seeing double-digit revenue growth and has more than 50 therapies in its pipeline, making it a good long-term investment.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...

Regeneron Pharmaceuticals (NASDAQ: REGN) reported strong Q1 earnings and a $3B share buyback. Analysts have mixed views on the stock.

Biotech company Regeneron (NASDAQ:REGN) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 19% year on year to $3.61 billion...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such a...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 7.1% in the afternoon session after its first-quarter 2026 earnings report revealed sig...

Regeneron (REGN) Q1 2026 Earnings Transcript

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 19% year on year to $3.61 billion. I...

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Wednesday morning. Here’s what to expect. Regeneron beat analysts’ revenue expectatio...